

28 February 2019

ASX Code: MXC

Resignation of Joint Company Secretary

MGC Pharmaceuticals Ltd (ASX: MXC or “the Company”) would like to announce the resignation of Ms Kate Sainty as Joint Company Secretary of the Company with an effective date of 28 February 2019. We express our appreciation to Ms Sainty for her contribution to the Company during her tenure.

Ms Sainty’s resignation comes as Mrs Rachel Kerr returns to her role as Company Secretary in a full-time capacity following maternity leave.

--End--

For further information, please contact:

Media Enquiries

Justin Kelly
Media and Capital Partners
+61 408 215 858
Justin.kelly@mcpartners.com.au

MGC Pharmaceuticals Ltd

Brett Mitchell
Executive Chairman
+61 8 6382 3390
info@mgcpharma.com.au

About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is an EU based BioPharma company with many years of technical clinical and commercial experience in the medical cannabis industry. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality Cannabinoids based pharmaceuticals products for the growing demand in the medical markets in Europe, North America and Australasia.

Follow us through our social media channels   